
Liwei Zhao

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/37039/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Detection of immunogenic cell death and its relevance for cancer therapy. Cell Death and Disease, 2020, 11, 1013.	2.7	466
2	Crizotinib-induced immunogenic cell death in non-small cell lung cancer. Nature Communications, 2019, 10, 1486.	5.8	189
3	elF2α phosphorylation is pathognomonic for immunogenic cell death. Cell Death and Differentiation, 2018, 25, 1375-1393.	5.0	162
4	Photodynamic therapy with redaporfin targets the endoplasmic reticulum and Golgi apparatus. EMBO Journal, 2018, 37, .	3.5	81
5	Immunosuppression by Mutated Calreticulin Released from Malignant Cells. Molecular Cell, 2020, 77, 748-760.e9.	4.5	77
6	Identification of pharmacological agents that induce HMGB1 release. Scientific Reports, 2017, 7, 14915.	1.6	37
7	Crizotinib – a tyrosine kinase inhibitor that stimulates immunogenic cell death. OncoImmunology, 2019, 8, e1596652.	2.1	25
8	PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer. Oncolmmunology, 2022, 11, .	2.1	25
9	Identification of pharmacological inhibitors of conventional protein secretion. Scientific Reports, 2018, 8, 14966.	1.6	21
10	Lysosomotropic agents including azithromycin, chloroquine and hydroxychloroquine activate the integrated stress response. Cell Death and Disease, 2021, 12, 6.	2.7	21
11	Surface-exposed and soluble calreticulin: conflicting biomarkers for cancer prognosis. Oncolmmunology, 2020, 9, 1792037.	2.1	17
12	Quantitation of calreticulin exposure associated with immunogenic cell death. Methods in Enzymology, 2020, 632, 1-13.	0.4	16
13	Redaporfin induces immunogenic cell death by selective destruction of the endoplasmic reticulum and the Colgi apparatus. Oncotarget, 2018, 9, 31169-31170.	0.8	15
14	Epigenetic anticancer agents cause HMGB1 release <i>in vivo</i> . Oncolmmunology, 2018, 7, e1431090.	2.1	12
15	A fluorescent biosensor-based platform for the discovery of immunogenic cancer cell death inducers. Oncolmmunology, 2019, 8, 1606665.	2.1	12
16	Secreted calreticulin mutants subvert anticancer immunosurveillance. Oncolmmunology, 2020, 9, 1708126.	2.1	11
17	Methods for measuring HMGB1 release during immunogenic cell death. Methods in Enzymology, 2019, 629, 177-193.	0.4	7
18	Development of a New Recurrence-Free Survival Prediction Nomogram for Patients with Primary Non-Muscle-Invasive Bladder Cancer Based on Preoperative Controlling Nutritional Status Score. Cancer Management and Research, 2021, Volume 13, 6473-6487.	0.9	5

Liwei Zhao

#	Article	IF	CITATIONS
19	Combination treatments with hydroxychloroquine and azithromycin are compatible with the the therapeutic induction of anticancer immune responses. Oncolmmunology, 2020, 9, 1789284.	2.1	4
20	Assessment of type I interferon responses as a feature of immunogenic cell death. Methods in Cell Biology, 2022, , 135-143.	0.5	4
21	Assessment of immunological memory formation in vivo. Methods in Cell Biology, 2022, , .	0.5	Ο